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Abstract
Background: The primary purpose of this study is to assess the existing evidence on the cost-effectiveness of
surgical interventions for the management of knee and hip osteoarthritis by systematically reviewing published
economic evaluation studies.
Methods: A systematic review was conducted for the period 2004 to 2016. Electronic databases were searched to
identify both trial and model based economic evaluation studies that evaluated surgical interventions for knee and
hip osteoarthritis.
Results: A total of 23 studies met the inclusion criteria and an assessment of these studies showed that total knee
arthroplasty (TKA), and total hip arthroplasty (THA) showed evidence of cost-effectiveness and improvement in
quality of life of the patients when compared to non-operative and non-surgical procedures. On the other hand,
even though delaying TKA and THA may lead to some cost savings in the short-run, the results from the study
showed that this was not a cost-effective option.
Conclusions: TKA and THA are cost-effective and should be recommended for the management of patients with
end stage/severe knee and hip OA. However, there needs to be additional studies to assess the cost-effectiveness
of other surgical interventions in order for definite conclusions to be reached.
Keywords: Osteoarthritis, Cost-effectiveness, Costs, Review
Background
Osteoarthritis (OA) is the most common form of
joint disease, and results from a progressive degenera-
tive change in the joint structure. OA is associated
with any joint in the body but the most commonly
affected are the hip and the knee [1]. It has been esti-
mated that about 251 million people suffer from knee
OA worldwide [2]. The prevalence of OA increases
with age, and with the constant rise in the global age-
ing population [3, 4], the economic burden of the dis-
ease is also likely to rise.
Osteoarthritis places a strain on scarce resources. For
example, in a recent study, the total annual direct cost
of osteoarthritis in the US was estimated to be double
that of similar patients who did not have osteoarthritis
[5]. In the UK, the total health care cost of osteoarthritis
is estimated at over £1 billion (2010 prices) [6]. Based
upon national survey data, Kortlarz et al. estimate the
increased insurer expenditure for women in the US with
osteoarthritis to be $4,833 [7]. For men with osteoarth-
ritis, the additional insurer cost was estimated as $4,036
[7]. There is therefore a need for cost-effective ap-
proaches for the management of OA.
Treatment and management of OA involves a multi-
disciplinary approach and various management options
include patient education and self-management, non-
pharmacological treatments and pharmacological treat-
ments. In the recently updated clinical guidelines for
management of OA, issued by the National Institute for
Health and Care Excellence (NICE), comprehensive and
integrated care which involves healthcare professionals,
patients and carers are among the key recommendations
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intended to ensure the maximum benefit for patients
[8]. Apart from these pharmacological and non-
pharmacological interventions, there are also surgical in-
terventions which are more expensive and are normally
limited to those patients who do not respond to other
forms of treatment. Due to the increase in the number
of older people, there has been an increase in the de-
mand for surgical interventions such as joint arthro-
plasty which has caused a rise in the costs associated
with OA [9–11].
Systematic reviews have assessed the cost-effectiveness
of pharmacological and non-pharmacological treatments
for OA [12–14]. However to the best of our knowledge,
a systematic review of economic evaluations assessing
surgical interventions for the management of OA has
never previously been published or reported. This study
is therefore aimed at reviewing published economic eval-
uations aimed at assessing and summarizing evidence on
the cost-effectiveness of surgical interventions for the
management of OA. The focus is on knee and hip OA
since they are the most common forms of OA.
Methods
The search and identification of papers followed a two-
stage process. The initial search included economic eval-
uations associated with any clinical trials or cohort
studies that assessed surgical, non-pharmacological and
pharmacological interventions for all types of OA. This
was necessary to meet the needs of the wider research
project. The search strategy outlined below reflects this
initial, broad scope.
Search strategy
Electronic databases (Ovid MEDLINE(R) In-Process &
Other Non-Indexed Citations and Ovid MEDLINE(R),
Ovid EMBASE Classic and EMBASE, EBM Reviews-
Cochrane Database of Systematic Review, EBM Reviews-
NHS Economic Evaluation Database, PubMed, INAHTA
database and HTA websites) were searched for economic
evaluations associated with any clinical trials or cohort-
based trials that assessed all types of treatment modal-
ities (pharmacological, non-pharmacological, surgical)
for all types of OA.
Additional literature which was considered as poten-
tially relevant was identified from the bibliographies of
the retrieved articles and search engines such as Google
Scholar. Any studies with limited access were retrieved
by emailing the author(s) and no language restrictions
were imposed. The searches were conducted between
2004 and 2016. This timeframe was chosen for prag-
matic reasons and in order to capture the most recent
studies. The detailed search terms that were used, has
been outlined in Additional file 1.
Selection of studies
All titles and abstracts of retrieved articles were screened
and any duplicates were excluded from the initial list.
Each article was then checked for suitability in terms of
their potential in assessing the cost-effectiveness and
economic analysis of various treatment modalities for
management of OA. Full text articles of these selected ti-
tles were retrieved and reviewed for further selection in
accordance to pre-specified inclusion and exclusion cri-
teria. The selection of articles was carried out independ-
ently by two reviewers [HK] and [RO]. Results from
each reviewer were compared and any differences were
resolved through consultation among reviewers.
It was from this broad pool of papers that the follow-
ing, more specific, inclusion and exclusion criteria were
applied, in order to identify studies falling within the
scope of this paper.
Inclusion criteria
The inclusion criteria for this systematic review were di-
vided into 5 main components as follows:
i. Population: Patients with knee or hip osteoarthritis
ii. Intervention: Surgical interventions (total knee
arthroplasty, total hip arthroplasty etc).
iii. Comparators: Any comparators (no interventions,
usual care, and other surgical modalities)
iv. Outcomes: Any outcomes for economic evaluations
(cost effectiveness, incremental cost-effectiveness ra-
tio or ICER)
v. Study design: Cost consequence analysis, cost-
benefit analysis, cost-effectiveness analysis, cost-
utility analysis both trial-based studies and model-
based economic analysis
Exclusion criteria
The exclusion criteria for this review were as follows:
i. Study designs that do not consider knee or hip OA
or study designs that combine OA patients with
other types of arthritis (rheumatoid arthritis, lupus
arthritis, ankylosing spondylitis)
ii. Partial or non-economic evaluation studies
iii. Ongoing studies and protocol
iv. Systematic reviews, narrative review, commentaries
and letters
v. Duplicated publications
Data extraction and methods of analysis and synthesis
The following data was extracted from the selected studies:
Study characteristics such as type of economic analysis,
population, interventions, comparators, perspective, time
horizon, and types of modelling used, effectiveness and
cost measures, main results, ICER, base-case outcomes
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and sensitivity analyses being used. A summary of the
studies relating to surgical interventions for the treatment
of hip and knee OA is presented in Table 1.
Assessment of the quality of studies
Assessment of the quality of included studies was per-
formed by using the Consolidated Health Economic
Evaluation Reporting Standards or CHEERS [15] (Add-
itional file 1) and Philips criteria checklist [16] (Add-
itional file 1) for model based studies. All included
studies were also quantitatively assessed using the Qual-
ity of Health Economic Studies (QHES) instrument
(Additional file 1) which was designed to evaluate the
appropriateness of the methodology, the validity and
transparency of the study results and the comprehen-
siveness of reporting the study itself [17].
Results
Search results
The initial (broad) search yielded 303 potentially rele-
vant articles and after reviewing the abstracts and apply-
ing the inclusion criteria, 121 studies were initially
included for full text review. After applying exclusion
criteria set out above, a total of 98 articles were ex-
cluded, mainly because they were duplicates (6 studies),
were not concerned with assessing surgical interventions
(38 studies), not limited to knee and hip OA patients (19
studies), not full economic evaluations (22 studies), pro-
tocols (3 studies) and systematic reviews (10 studies). A
total of 23 studies were included in the final sample for
this paper (Fig. 1).
Summary of selected studies
All studies included in this review were published be-
tween 2004 and 2016 and were conducted across nine
different countries (USA, Italy, Canada, Australia,
Finland, UK, Singapore, Belgium and Romania). The
types of economic evaluations conducted were mainly
cost-utility analysis (78%) and cost-effectiveness ana-
lysis (13%) with one study conducting a cost-benefit
analysis [18] and another conducting both a cost-
utility analysis and a cost-effectiveness analysis [19].
Sixteen studies were model based, whilst six were
trial based (Table 1). Most studies adopted either a
healthcare (nine studies) or a societal perspective
(eight studies). Two studies however adopted both a
healthcare and a societal perspective [19, 20]. Of the
remaining studies, four did not specifically mention
the perspective that was adopted [21–24].
Three studies only incorporated direct medical costs
in their analysis even though they stated that they
adopted a societal perspective [25–27]. Most studies
described the comparators that were used; one study
stated that the comparator of choice was a non-
operative strategy [28] but did not give any specific
details about the non-operative strategy used. For
studies that used the QALY as an outcome measure,
various health-related quality of life (HR-QoL) instru-
ments such as the SF-36, EQ-5D, SF-6D, 15-
Dimensional Utility Index (15D), Health Utility Index
(HUI) and Health Assessment Questionnaire (HAQ)
were used. Two studies [25, 29], however, did not
specifically mention the tools that were used to derive
the QALY estimates. Apart from the generic HR-QoL
instruments, some studies utilised disease-specific
health state instruments. For instance, Räsänen et al
[28] used Harris Hip Score (HHS) and Knee Society
Score (KSS) as complementary disease-specific tools
for the 15D generic instrument used in the study.
Other disease-specific tools used were Oxford Hip
Score (OHS), Oxford Knee Score (OKS) and Western
Ontario and McMaster Universities Osteoarthritis
Index (WOMAC). The most widely used tool by
healthcare providers in assessing OA patients is
WOMAC Osteoarthritis Index which consists of 24
items used to evaluate pain, stiffness and physical
functions of OA patients in daily living [30].
Cost-effectiveness of interventions for the management
of knee and hip OA
For surgical modalities for knee OA, the most common
intervention was total knee arthroplasty whilst the most
common surgical modality for hip OA was total hip
arthroplasty.
Cost-effectiveness of Total Knee Arthroplasty (TKA)
TKA versus non-surgical/non operative strategies
Four studies compared TKA to non-operative/non-
surgical strategies [18, 28, 31, 32] and all studies
concluded that TKA is a cost-effective intervention.
Of these, three studies adopted a societal perspective
[18, 31, 32] whilst the fourth study [28] adopted a
healthcare provider perspective. The aim of the first
study [18] was to assess the cost-effectiveness of
TKA in the younger working population and used a
Markov model to assess the cost-effectiveness of
TKA over a 30 year period in a hypothetical 50 year
old patient with severe OA. The second study also
used a Markov model to estimate the lifetime cost-
effectiveness of TKA in patients with end stage OA
of the knee [31]. The remaining two studies [28, 32]
assessed the short term cost-effectiveness of TKA
using trial-based and cohort studies and did not limit
the population included in their respective studies by
age or stage of the disease. A summary of results is
presented in Table 2.
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TKA versus Unicondylar/Unicompartmental Knee
Arthroplasty (UKA)
Five studies compared TKA with UKA to determine the
most cost-effective option [21, 25, 27, 33, 34]. The first
study [27] looked at cost-effectiveness over 2 years using
a prospective observational study and found that TKA
was associated with both a higher cost and a QALY gain,
but could not be 95% confident that TKA is cost-
effective due to the short length of their study. The sec-
ond study [21] found that TKA was associated with
higher costs and longer hospital stays in the short run
whilst UKA was associated with significantly poorer long
term survival rates and higher possibility for revision
surgery or secondary TKA. The study noted that the
cost saved by lower implant prices and shorter hospital
stays may not be able to cover the cost of extra revision
surgeries that are needed in the future [21]. Peersman et
al. [34] used a Markov model to assess cost-effectiveness
in four different age groups (<55, 55-65, 65-75 and 75+)
and found that in all age groups UKA was associated
with cost reductions and health gains. The conclusion
from this study was that TKA was not cost-effective
when compared to UKA. However, this study did not
adopt a societal perspective. The study by Soohoo et al.
[25] used a decision model to assess cost-effectiveness in
patients with end stage unicompartmental knee OA and
found UKA to be cost-effective compared to TKA if the
durability and function of UKA are assumed to be the
same as TKA. The final study [33] compared TKA
with UKA and High Tibial Osteotomy (HTO) in
younger patients (50-60 years) with unicompartmental
OA using a Markov model and from a societal per-
spective. The study concluded that TKA had just a
31% chance of being cost-effective compared with
Fig. 1 Flow diagram of the study selection process
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Table 2 Summary of main results
No. Author & Year Intervention(s) evaluated Key result(s) Conclusion QHES
scoresa
1. Higashi et al, [35] Total replacement of hip and
knee
Both hip and knee replacements
were cost-effective compared to
'doing nothing' at the pre-
defined threshold level of AUD
50,000 per DALY.
• THR : AUD 7100 to 15000 per
DALY with different time cost &
cost offset
• TKR : AUD 15000 to 26000 per
DALY with different time cost &
cost offset
Both hip and knee replacements
are cost-effective interventions to
improve the quality of life of
people with OA.
70
2. Bedair et al, [18] Total knee arthroplasty (TKA) Treatment with TKA has a higher
initial cost, but the cost benefit
in favor of TKA approximately
3.5 years after surgery (a
difference of US$69,800 over the
same time period when treated
with non-operative strategies
The total economic cost to
society for treatment of severe
knee OA in a relatively young
working person is markedly
lower with TKA than it is with
non-operative treatment.
74
3. Losina et al, [36] Total knee arthroplasty (TKA)
performed in low, medium and
high volume hospitals
- Base-case ICER : US$18300 /
QALY
- If willingness to pay (WTP) to
improve QOL were set at US$50
000 per QALY, TKA had a 93%
chance of being the preferred
choice (ie, TKA had the highest
net benefit) compared with no
TKA.
- Low-risk patients : 96% chance
that TKA would be preferred to
no TKA if WTP US$50 000 per
QALY
- High-risk patients : 83% chance
that TKA would be preferred to
no TKA
- TKA appears to be cost-
effective in the US Medicare-
aged population, as currently
practiced across all risk groups.
- Policy decisions should be
made on the basis of available
local options for TKA.
- However, when a high-volume
hospital is available, TKAs per-
formed in a high-volume hospital
confer even greater value per
dollar spent than TKAs per-
formed in low-volume centres.
73
4. Ruiz et al, [31] Total knee arthroplasty (TKA) - Relative to nonsurgical
treatment, the mean lifetime net
societal savings per patient
resulting from TKA was
US$18,930
- Each TKA increased lifetime
direct costs by a mean of
US$20,635, while the societal
savings in lower indirect costs
from improved functional status
averaged US$39,565.
- Considering only direct costs,
the average ICER was US$5656
per QALY gained for TKA in the
entire cohort and US$12,410 for
those of 80 years old and older.
Overall, TKA was cost-effective
across all age groups, assuming a
willingness-to-pay threshold of
US$50,000 per QALY gained
taken from societal perspective.
71
5. Waimann et al, [32] Total knee arthroplasty (TKA) - The ICERs for WOMAC
improvement at 6 months were
as follows:
1) US$33,345 to achieve an MCID
2) US$25,255 per each
WOMAC20 improvement,
3) US$35,274 per each
WOMAC50 improvement
4) US$56,908 per each
WOMAC70 improvement
- TKA would be a cost-effective
intervention if the WTP amount
for the minimum clinically signifi-
cant absolute or relative im-
provement were US$50,000.
Although there was no
established WTP value for
WOMAC change, TKA appeared
to be a cost-effective interven-
tion for end-stage knee OA at
both low and high levels of im-
provement in the patients’ pain
and function.
60
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Table 2 Summary of main results (Continued)
6. Xie et al, [27] Total knee arthroplasty (TKA) - ICUR was US$65,245/QALY from
the societal perspective.
- The probability of TKA being a
cost-effective strategy is less than
0.4 from the societal or patients’
perspective if the WTP is
US$50,000/QALY.
- In contrast, the probability that
TKR is a cost effective strategy is
0.7 from the government’s
perspective if the WTP is only
US$10,000/QALY
TKA gained more QALYs at
higher costs compared to UKA.
However, a long-term prospect-
ive study is necessary to deter-
mine the cost-effectiveness of
TKR and UKA.
62
7. Koskinen et al,[21] Unicondylar knee arthroplasty
(UKA)
- The mean cost of one revision
from UKA to TKA was €8,660
including implant, hospital stay,
operation, and other direct costs.
Thus, the costs saved by lower
implant prices and shorter
hospital stay for UKA as
compared to TKA would not
cover the costs of the extra
revisions.
At a nationwide level, UKA had
significantly poorer long-term
survival than TKA. UKA did not
even have a theoretical cost
benefit over TKA in the study.
Based on the results, widespread
use of UKA in the treatment of
unicompartmental OA of the
knee cannot be recommended.
33
8. SooHoo et al, [25] Unicondylar knee arthroplasty
(UKA)
- In reference case, UKA has only
small gain of QALY (0.02) and
minimal increment in costs, from
US$18,995 to US$19,000
compared to TKA
- Reference case ICER : US$277
per QALY gained.
- In lower durability / survival of
UKA in terms of function, UKA
becomes less effective and more
costly.
- If durability / survival of TKA is
longer (range 15 to 20 years),
TKR becomes more cost
effective.
- If TKR durability is 20 years, the
ICER for UKA would be $45,958
per QALY gained when UKA is
assumed to be functional up to
17 years (abelow threshold)
This analysis demonstrates the
potential for UKA to be a cost-
effective alternative to TKA, de-
pending on the cost as well as
the durability and function of a
UKA.
59
9. Li et al, 2013 [22] KineSpring Knee Implant System
- intermediate treatment
between conservative care and
joint-altering surgery targeting
the treatment gap in knee OA
patients.
- Assuming the durability of
10 years, the cost-utility ratio of
each intervention compared to
no treatment :
• KineSpring : €3,402 ± 4,168/
QALY,
• Surgical interventions : €4,899 ±
1,094/QALY
• Conservative treatments :
€9,996 ± 13,612/QALY
The KineSpring Knee Implant
System for knee OA is a cost-
effective strategy over other sur-
gical and conservative treatments
for patients in Germany.
44
10. Suter et al, [26] “innovative” TKA implants - Innovative implants offered
≥50% decrease in long-term TKA
failure at ≤50% increased cost of-
fered ICERs < US$100,000 regard-
less of age or baseline
comorbidity.
- Innovative implant provided a
20% decrease in long-term failure
at 50% increased cost provided
ICERs < US$150,000 per QALY
gained only among healthy 50–
59-year-olds.
- Increasing short-term failure,
consistent with recent device
Innovative implants must
decrease actual TKA failure, not
just radiographic wear, by 50–
55% or more over standard
implants to be broadly cost-
effective.
65
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Table 2 Summary of main results (Continued)
failures, reduced cost-
effectiveness in all groups.
11. Mota, [38] Early primary THA - Early THA has cost-effectiveness
ratios of €4100 or below in all
cases.
- Among 80-year-olds, early THA
is (extended) dominant = ICER of
€20,406.
- Delayed THA is not cost-
effective at any threshold for
base-case scenario.
- At age 65 years, the ICER for
THA over delayed THA was €987
in men and €466 in women.
In summary, results suggest that
THA is a cost-effective treatment
option, and in general should be
offered without delay to func-
tionally independent patients
with severe OA.
82
12. Räsänen et al, [28] 1. Primary THA
2. Secondary / revision THA
3. Primary TKA
- The cost per QALY gained
(ICUR) was lowest in the primary
THA group , followed by primary
TKA & revision THA.
• Primary THA : €6710 per QALY
gained
• Primary TKA : €13,995 per QALY
gained
• Revision THA : €52,274 per
QALY gained
Hip and knee replacement both
improve HRQoL. The cost per
QALY gained from knee
replacement is twice that gained
from hip replacement.
49
13. Bozic et al, [29] Metal-on-metal hip resurfacing
arthroplasty (MoM-HRA)
- Lowest ICER [most cost-
effective] : men age 55 to 64
(US$28,614/QALY gain)
- Three groups with ICER below
threshold [below US$50,000/
QALY gained) :
• men age 55 to 64 (as above)
• women younger than 55
(US$47,468/QALY gained)
• men younger than 55
(US$48,882/ QALY gained)
MoM-HRA could be clinically
advantageous and cost-effective
in younger men and women.
Further research on the compara-
tive effectiveness of MoM-HRA
versus THA should include as-
sessments of the quality of life
and resource use in addition to
the clinical outcomes associated
with both procedures.
82
14. Heintzbergen et al, [37] Metal-on-metal hip resurfacing
arthroplasty (MoM-HRA)
- Base-case : MoM HRA domi-
nates with -CAD $583 and mean
difference QALY 0.079.
- With WTP at CAD$50,000/QALY
gain, probability HRA is cost-
effective are:-
• base case : 58%
• male 60 years : 9%
• male 40 years : 92% - most
cost-effective
- The results and uncertainty in
base-case analyses suggest that
in terms of cost-effectiveness,
there is little difference between
MoM HRA and THA.
- In terms of gender, MoM HRA
was preferable in men and THA
in women
- Age wise, MoM HRA was
preferable in younger patients
and THA in older patients
On average, MoM-HRA was pre-
ferred to THA for younger and
male patients, but THA is still a
reasonable option if the patient
or clinician prefers given the
small absolute differences be-
tween the options and the confi-
dence ellipses around the cost-
effectiveness estimates.
81
15. Di Tanna et al, [39] Cementless fixation technique for
THA
- Base-case ICER : €2402 per "revi-
sion-free" life year
- Cementless strategy dominant
for patients up to 42-y-old (i.e.,
less costly and more beneficial
compared with the hybrid
solution)
- 43-yr-old onwards, it still re-
mains more effective but with an
additional cost : the resulting
Following a deterministic
sensitivity analysis, hybrid and
cementless fixation showed a
dominance profile for patients
older than 83 y and younger
than 43 y, whereas for all ages in
between, there is a progressive
increase in the ICER of
cementless prostheses.
62
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Table 2 Summary of main results (Continued)
ICERs showed a direct propor-
tionality to increasing age
- From CEAC:
• the cementless intervention as
a strategy with a high probability
(0.88) of being cost effective at
70 y from values of WTP above
€2400
• In case of a 75-y-old patient
with WTP of €9000, a cementless
approach results cost effective
with a probability of 0.89.
16. Pennington et al, [41] Cementless and hybrid prosthesis
for THA
- The ICER for a hybrid prosthesis
compared with a cemented
prosthesis was about £2100 per
QALY for men and £2500 for
women.
- For men aged 60 or 80 and for
women aged 60, hybrid
prostheses gave the highest
expected net benefit and had
the highest probability of being
the most cost effective
prosthesis.
- For women aged 80, cemented
prostheses were most cost
effective.
- Hybrid prostheses remained
likely to be the most cost
effective option for men and
women aged 70.
- Cemented prostheses are the
cheapest option, but hybrid
prostheses lead to greater gains
in mean post-operative quality of
life and are the most cost effect-
ive alternative for most patients.
- Cementless prostheses do not
improve health outcomes
sufficiently to justify their higher
costs.
82
17. Konopka et al, [33] High tibial osteotomy (HTO) and
unicompartmental knee
arthroplasty (UKA)
- Base case QALYs : 14.62 (HTO),
14.63 (UKA) and 14.64 (TKA).
- Discounted total direct medical
costs : $20,436 (HTO), $24,637
(UKA) and $24,761 (TKA)
- ICER for TKA: $231,900/ QALY
- ICER for UKA: $420,100/ QALY
- PSA: At a WTP threshold of
$50,000 per QALY, HTO was cost-
effective 57% of the time; TKA
24%; and UKA 19%.
- At a WTP threshold of $100,000
per QALY, high HTO 43% of time,
TKA 31%; and UKA 26%.
In 50 to 60-year-old patients with
medial unicompartmental knee
OA, HTO is an attractive option
compared with UKA and TKA
The cost-effectiveness of HTO
and of UKA depends on rates of
conversion to TKA and the clin-
ical outcomes of the conversions.
78
18. Marsh et al, [19] Arthroscopic surgery (partial
resection and debridement of
degenerative meniscal tears and/
or articular cartilage) in addition
to non-operative treatments
- The ICER was $140.94 (societal),
or $120.83 (payer) per one-point
improvement on the 2400 point
WOMAC total score, translating
to $28,188 (societal) and $24,166
(payer) for a clinically important
improvement.
- The ICUR was equal to
− $110,569 (societal) or
− $94,792.50 (payer) per QALY
gained, where the negative value
indicates paying more for a
worse outcome.
- Uncertainty estimates suggest
that even if WTP $400 000 to
achieve a clinically important
improvement in WOMAC score,
or ≥ $50 000 for an additional
QALY, there is <20% probability
that the addition of arthroscopy
is cost-effective compared with
nonoperative therapies only.
Arthroscopic debridement of
degenerative articular cartilage
and resection of degenerative
meniscal tears in addition to
nonoperative treatments for knee
OA is not an economically
attractive treatment option
compared with non-operative
treatment only, regardless of
willingness-to-pay value.
74
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Table 2 Summary of main results (Continued)
19. Mather et al, [20] Primary TKA without delay - In the base case, a 2-year wait-
time both with and without a
non-operative treatment bridge
resulted in a lower number of
average QALYs gained (11.57 (no
bridge) and 11.95 (bridge) vs.
12.14 (no delay).
- The ICER comparing wait-time
with no bridge to TKA without
delay was $2,901/QALY.
- When comparing TKA without
delay to waiting with non-
operative bridge, TKA without
delay produced greater utility at
a lower cost to society.
TKA without delay is the
preferred cost-effective treatment
strategy when compared to a
waiting for TKA without non-
operative bridge. TKA without
delay is cost saving when a non-
operative bridge is used during
the waiting period. As it is un-
likely that patients waiting for
TKA would not receive non-
operative treatment, TKA without
delay may be an overall cost-
saving health care delivery
strategy.
76
20. Peersman et al, [34] UKA - UKA was associated with cost
reduction compared with
primary TKA of –€2,807 and a
utility gain of 0.04 QALYs. UKA
was therefore considered
superior to TKA.
- Analysis determined that the
model is sensitive to clinical
effectiveness, and that a marginal
reduction in the clinical
performance of UKA would lead
to TKA being the more cost-
effective solution.
- The acceptability curve shows
that the probability that the ICER
falls below the threshold of:
€10,000 (77.1%) , €25,000 (65.1%)
and €50,000 (60.5%).
UKA yields clear advantages in
terms of costs and marginal
advantages in terms of health
effects, in comparison with TKA.
72
21. Pennington et al, [23] Different brands within types of
hips prosthesis (cemented,
cementless and hybrid)
For women with OA aged
70 years, the Exeter V40 Elite Plus
Ogee had the lowest risk of
revision (5.9% revision risk, 9.0
QALYs) and the CPT Trilogy had
the highest QALYs (10.9%
revision risk, 9.3 QALYs).
- Compared with the Corail
Pinnacle (the most commonly
used brand), the CPT Trilogy is
most cost effective, with an
incremental net monetary
benefit of £876.
- Differences in cost effectiveness
between the hybrid CPT Trilogy
and Exeter V40 Trident and the
cementless Corail Pinnacle and
Taperloc Exceed were small.
The hybrid CPT-Trilogy was the
most cost effective brand but dif-
ferences with the hybrid Exeter
V40-Trident and the cementless
Corail-Pinnacle and Taperloc-
Exceed were small. Our study
shows the importance of linking
PROMs with data on rates of revi-
sion after THA but given the ex-
tended period of recovery after a
THA, collecting further PROMs
and QoL beyond the first six
months after THA is an important
next step which would
strengthen future economic eval-
uations of brands of hip
prostheses.
57
22. Pulikottil-Jacob et al, [40] - Metal head (cemented stem)
on cemented polyethy-lene cup,
CeMoP
- Metal head (cement-less stem)
on cement-less hydroxyapetite
coated metal cup (polyethylene
liner), CeLMoP
- Ceramic head (cementless
stem) on cementless hydroxyl-
apetite coated metal cup (cer-
amic liner), CeLCoC
- Hybrid metal head (cemented
stem) on cementless hydroxyl-
apetite coated metal cup (poly-
ethylene liner), HyMoP
- base-case analysis : At a WTP
£20,000 per QALY, a cemented
prosthesis with metal-
onpolyethylene or ceramic-on-
polyethylene bearings had the
greatest probability of being
cost-effective for all groups of
age and gender over a lifetime.
- The differences in QALYs
between categories were
extremely small and differences
in mean costs were borderline,
between only £2550 and £3000
over a lifetime for all
comparisons, irrespective of age
or gender.
On the basis of such small
differences and such
considerable uncertainties, it is
difficult to make a comparison
between the cost-effectiveness
of different types of prosthesis.
Until better data dealing with
costs and outcomes become
available, it is difficult to justify
the recommendation of one type
of device over another on con-
siderations of cost effectiveness
alone. The choice of prosthesis
should be determined by rates
of revision, local costs and the
preferences of both the surgeon
and the patient
62
Kamaruzaman et al. BMC Musculoskeletal Disorders  (2017) 18:183 Page 12 of 17
UKA and THO and that HTO provided value for
money in 50 to 60 year old patients. A summary of
results are presented in Table 2.
TKA versus other treatments
One study compared TKA with a do nothing approach
over patients lifetime in the Australian population from
a health system perspective [35], and found TKA to be a
cost-effective intervention. Another study [20] compared
early and delayed TKA (with and without a non opera-
tive bridge) in a cohort of 60 year olds from a societal
perspective. The study found that TKA without delay is
the preferred cost-effective treatment strategy when
compared to waiting for TKA without non-operative
bridge. This study noted that as it is unlikely that pa-
tients waiting for TKA would not receive non-operative
treatment, TKA without delay may be an overall cost-
saving health care delivery strategy.
Another study [26] compared two types of TKA tech-
niques (standard and innovative TKA) and concluded
that innovative implants would be cost-effective if they
reduce TKA failure by approximately 50%. Finally,
Losina et al [36] used a Markov model to simulate costs
and QALY gains for TKA, carried out in low, medium
and high volume hospitals; and using no TKA as com-
parator. Findings relate to the Medicare aged population
in the US. TKA was found to be cost-effective across all
risk groups and, usurpingly, to be more cost-effective
when carried out in high volume hospitals (Table 2).
Cost-effectiveness of Total Hip Arthroplasty (THA)
THA vs Metal on metal hip resurfacing arthroplasty
(MoM-HRA)
Metal-on-metal hip resurfacing arthroplasty (MoM-
HRA) was considered as an alternative in two studies
[29, 37]. The first study used a Markov model to com-
pare the cost-effectiveness of THA and MoM-HRA in
patients aged 50 years and over from a health system
perspective over a 30 year period and the results show
that MoM-HRA is cost-effective in younger patients and
although MoM-HRA showed improvements in QALYs,
further research is needed to reach a definite conclusion
as to which is the most cost-effective intervention [29].
The second study used a Markov model to assess the
cost-effectiveness of THA compared with MoM-HRA
from a health system perspective over a 15 year period.
The study concluded that age wise, MoM-HRA was
preferable in younger patients and THA in older pa-
tients and gender wise, MoM-HRA was more preferable
in men and THA in women [37].
THA vs other strategies
One study compared THA to a non-operative strategy
from a health care perspective and found THA to be a
cost-effective intervention [28]. Another study compared
the intervention to a do nothing approach over patients’
lifetime in the Australian population from a health sys-
tem perspective and found THA to be cost-effective
[35]. The study by Mota used a Markov modelling ap-
proach to compare early and delayed hip arthroplasty in
a cohort of patients based on sex and age (50-59 years,
60-74 years and 75 years and over) from a health pro-
vider perspective and the results from this study suggest
that early THA is a cost-effective option across groups
based on age and sex [38].
Four studies compared various techniques for THA.
The first study [39] compared two techniques for THA
(cementless and hybrid) over patients lifetime using a
Markov model and found the cementless technique to
be cost-effective compared to the hybrid technique in
most cases. However, the cementless technique was
found to be dominant in patients less than 43 years
whilst the hybrid technique seemed to be dominant in
patients aged 83 and over.
Table 2 Summary of main results (Continued)
- Ceramic head (cemented stem)
on cemented polyethy-lene cup,
CeCoP
- There are large uncertainties,
particularly regarding the costs of
prostheses and the estimates of
lifetime QOL.
23. Stan et al, [24] - Unilateral TKA (G2)
- TKA following HTO (G3)
- No statistically significant
differences was found between
G2 and G3 regarding clinical or
radiological outcomes.
- Median benefit estimate for
patients who did not previously
suffered a HTO procedure was
smaller then benefit for those
who did.
- A median CER of 1800 € /QALY
was found based on the EuroQol
scores for G1; 1268 € / QALY for
G2, and 1975 € / QALY for G3.
Conservative management for
knee OA is neither clinically
effective for pain or disease
progression nor cost effective,
when applied for late stages of
OA. TKA proved to be a cost
effective procedure in treating
knee OA. This study reported the
lowest cost per QALY in the
literature for TKA. TKA after HTO
is technically more difficult and
lead to a greater rate of
perioperative complications
56
aGood quality = ≥75 Moderate quality = 50 to 74 Poor quality = <50
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The second study assessed the lifetime cost-
effectiveness of cemented, cementless and hybrid
techniques and found the hybrid to be the most cost-
effective compared to cemented and cementless in 60,
70 and 80 year old patients. The results obtained in this
study were similar for both men and women [23]. The
third study [40] compared five different techniques for
THA from an NHS/PSS perspective and concluded that
it is difficult to make a choice between techniques based
on cost-effectiveness grounds alone. The fourth study
assessed the cost-effectiveness of three types of pros-
thesis for hip replacement (cemented, cementless and
hybrid) in adults aged between 55 and 84 years. The
study found the hybrid prosthesis to be the most cost-
effective across all age groups, with the exception of
80 year old women where the cemented prosthesis was
the most cost-effective [41].
Cost-effectiveness of other surgical interventions
For studies that considered implant systems, one study
evaluated the KineSpring implant system and found it to
be cost-effective compared to other surgical and conser-
vative treatments [22]. Another study compared arthro-
scopic surgery with a non-operative treatment and
found that arthroscopic surgery was not a cost-effective
option [19]. A summary of the results and conclusions
of studies assessing the cost-effectiveness of surgical in-
terventions is presented in Table 2.
Overall quality of included studies
Based on the Quality of Health Economic Studies (QHES)
instrument, a total of six studies were categorised as good
quality with scores of 75 and above whilst fourteen other
studies were categorised as moderate quality with scores
between 50 to 74 (Table 2 and Additional file 1). Three
studies had scores below 50 [21, 22, 28] and a close exam-
ination of these studies revealed striking flaws such as not
reporting the source of transition probabilities, perspec-
tives, discount rate, cycle length and time horizon. One
study [22] did not perform any sensitivity analysis to deal
with the sampling uncertainty or give any details of the
source of effectiveness data.
Fourteen out of the eighteen model based studies used
Markov/semi-Markov models due to the chronic nature
of OA and the ability of such models to handle recurrent
events. Other model types that were used include deci-
sion tree modelling [25] and discrete-event simulation
(DES) which has the flexibility to accommodate a richer
structure without making it unmanageable in size [35].
Only one study did not specify which model type was
used as the basis of its economic evaluation [22]. The
time horizon used in the model based studies varied
from one year to lifetime and most of the studies chose
a 1-year cycle length for transitions to occur from one
health state to another. For those studies that accounted
for revision of surgery and failure of implant as one of
the outcomes, one year is considered as a reasonable
time to decide for further management, should any of
the events occur. The most commonly used sensitivity
analysis in the model-based economic evaluations in this
review is probabilistic sensitivity analysis. This involves
specifying distributions for model parameters to repre-
sent uncertainty in their estimation followed by employ-
ing Monte Carlo simulation to select values at random
from those distributions [42]. Other types of sensitivity
analysis used were deterministic, one-way and two-way
sensitivity analysis, subgroup analysis, regression analysis
and scenario analysis.
Discussion
This systematic review was conducted with the objective
of assessing the cost-effectiveness of surgical interven-
tions for the treatment of knee and hip OA. Overall, the
review found that most studies considered the most im-
portant components pertinent to economic analyses
such as perspective, currency, price year and time hori-
zon. Total knee arthroplasty, total hip arthroplasty and
metal-on-metal hip resurfacing arthroplasty showed evi-
dence of cost-effectiveness and improvement in quality
of life of the patients. However, this depended on the
population that was considered and the interventions
that they were compared to. For example, TKA and
THA were found to be cost-effective for patients with
severe or end-stage knee or hip OA across all age groups
and when compared to non-operative strategies. Regard-
less of perspective adopted, TKA and THA remain
among the most effective interventions in terms of im-
provements in quality of life of OA patients. Compared
to early primary THA or TKA, the findings suggest that
delayed total hip arthroplasty was not cost-effective [38].
MoM-HRA surgery was more cost-effective in younger
patients.
More than half of the studies in this review used
decision-analytic models and as expected, some of the
earlier studies [25, 43] used decision trees to analyse the
cost-effectiveness of the interventions of interest, whilst
the more recent studies utilised Markov models. This is
an indication that adequate information on model struc-
tures is now readily available and guidelines are being
adhered to. Based on the chronic nature of the disease
and potential of recurrence of the events that may occur
during disease progression in OA, Markov models have
been shown to be the most suitable decision-analytic
model for this condition since they provide a far more
convenient way of modelling prognosis for clinical prob-
lems with ongoing risk whereby events may re-occur
and when the utility of an outcome depends on when it
occurs [44]. One study employed a discrete-event
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simulation (DES) model to assess the cost-effectiveness
of total hip and knee arthroplasty in Australia [35]. The
literature has shown that DES is able to represent the
course of a disease more naturally and is best used in a
condition where interaction at individual or patient level
is a significant component in modelling [45, 46].
Strengths and limitations of the study
To the best of our knowledge, this is the only systematic
review pertaining to the cost-effectiveness of surgical
treatment modalities in management of osteoarthritis. In
addition, methodological issues related with economic
evaluations of surgical interventions in management of
OA were also assessed and reported in this study. This
study critically assessed the quality of included studies
both qualitatively with the Philips and CHEERS check-
lists as well as quantitatively using the QHES scoring
tool.
Because a broader search strategy was initially
adopted, a large number of studies were hand searched.
This may mean that we have been able to identify a lar-
ger number of relevant papers than if the initial search
criteria had been limited to surgical interventions for hip
and knee OA.
Limitations of the study include the following: Due to
the study aims and the need to include as many studies
as possible, we did not exclude any studies based on the
results of the quality checks. Hence, the robustness of
this systematic review may possibly be affected by the
poor quality studies included in this report. In addition
to this, the quality assessment was carried out by one re-
viewer. Second, studies that were included in this review
were conducted across nine countries which may lead to
problems such as generalisability and transferability of
the study findings to other settings due to differences in
factors such as clinical practice, prices and epidemiology
of disease [47, 48]. In addition to this, guidance in many
countries does not consider economic data to be trans-
ferable to their settings in most cases [49, 50]. As a re-
sult, care must be taken when interpreting the results of
this study in a particular context.
Policy implications and recommendations
Clinical guidelines by the National Institute for Health
and Care Excellence in the UK recommend a holistic ap-
proach to osteoarthritis assessment and management
[8]. The guidelines advocate for patient education and
self-management to enhance understanding of the con-
dition and its management. Unfortunately, the informa-
tion on economic analyses in the guidelines is confined
to pharmacological and conventional treatments. Cost-
effectiveness findings related to surgical interventions
were merely focused on time to referral for surgery as
being highlighted in the guidelines by National
Collaborating Centre for Chronic Conditions [51]. It is
therefore recommended that guidelines should also in-
clude suggestions for the use of surgical interventions as
well as other forms of treatments and management tech-
niques. One of the concerns around surgical interven-
tions such as arthroplasty relates to the cost implications
surrounding it. It may be argued that avoiding or delay-
ing these surgical procedures may have a positive impact
on health budgets through savings. However, it should
be noted that delaying such a procedure may have a det-
rimental effect on the quality of life of patients and may
lead to additional costs down the line. Studies included
in this review concluded that delaying arthroplasty (both
knee and hip) was not a cost-effective option and that
the health related quality of life lost as a result of the
delay is greater than the savings in costs that may occur
from delaying the procedure [38]. It is therefore sug-
gested that future cost-effectiveness studies assess the
cost-effectiveness of delaying surgery in various sub-
groups of patients and in various settings in order to
reach a consensus about when the operation should be
conducted and when delaying surgery would yield the
optimum results.
Although interventions such as THA have been shown
to be cost-effective, there needs to be additional studies
comparing the various types of THA surgeries in order
to maximise benefits from the available resources. In
addition, other interventions such as MoM-HRA have
been shown to be cost-effective in younger patients [37].
Therefore health policy makers should take such evi-
dence into consideration when providing guidance. Pol-
icy makers and stakeholders should therefore consider
TKA and THA as opposed to non-operative/non surgi-
cal strategies particularly for patients with severe/ad-
vanced stage OA [18]. From this review, it is clear that
there is limited evidence with respect to other forms of
surgical treatments. It is therefore suggested that add-
itional studies should be conducted in order to deter-
mine the cost-effectiveness of other forms of surgical
interventions for both knee and hip OA.
This study found that approximately 36% percent of
studies limited their analysis to a healthcare perspective.
It should however be noted that a large proportion of
the economic burden of OA is related to indirect costs
and productivity losses [6]. Thus, the societal perspective
has the potential to capture all important impacts on the
whole society. Recent guidelines suggest that due to the
chronic nature of OA, a broader societal perspective is
preferred [9, 52]. It should however be recognised that
national guidelines such as those in the UK recommend
that economic analysis should be undertaken from a
health service perspective [53] and as a result, analysts
in countries like the UK might limit their study to the
health service perspective. However, it is suggested that
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all studies should also consider the societal perspective
within sensitivity analysis in order to provide a better
picture of the true burden associated with OA and also
ensure that the results are more generalisable to other
settings.
Conclusions
This review assessed the cost-effectiveness of surgical in-
terventions for the management of knee and hip osteo-
arthritis and the results suggest that TKA and THA are
cost-effective interventions particularly when compared
to non-operative strategies and also when the operation
is not delayed. However, there is the need for more stud-
ies assessing the cost-effectiveness of other surgical mo-
dalities. In addition, most of the identified studies were
considered to have moderate quality. It is therefore rec-
ommended that more cost-effectiveness studies with
high methodological standards are conducted.
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